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Longitudinal measures of pulmonary function are a fundamental part of care for older children and
adults with cystic ﬁbrosis. The dilemma for the clinician caring for infants with cystic ﬁbrosis is how to
best objectively assess and treat early lung disease to maintain good lung health for as long as possible. In
this report, we present two cases where infant pulmonary function testing revealed an unexpected
degree of airway pathology that altered our clinical decision making. Following treatment with intra-
venous antibiotics, infant pulmonary function tests demonstrated dramatic improvement. These cases
demonstrate the utility of infant pulmonary function testing in guiding the management of infants with
cystic ﬁbrosis.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Objective assessment of lung health using pulmonary function
testing, particularly spirometry, is a fundamental part of care for
patients with cystic ﬁbrosis (CF). Clinical guidelines recommend
following serial pulmonary function tests when feasible to guide
therapy, to assess response to therapies, and to provide an objective
assessment of lung disease.1 The technical requirements for
conventional pulmonary function testing generally limit their use
to patients older than 5 years of age.
Signiﬁcant progress has beenmade over the past two decades in
developing infant lung function tests. Recent reviews suggest that
these techniques permit the investigation of early lung disease,2
although multicenter trials are needed to assess their clinical
utility as outcome measures.3 In his review of the clinical applica-
tions of infant lung function testing, Frey concludes that infant lung
function testing is ‘‘ready to be introduced into the clinical world’’.4
Theuseof infant pulmonary function testing (IPFT) inCFhas been
limited to small numbers of longitudinal assessments, descriptions
of CF populations, and research aimed at establishing IPFT tech-
niques.5–7 Ranganathanand colleagues5made repeatedmeasures of
lung function in newly diagnosed infants with CF. They found thataised volume rapid thor-
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rved.lung functionwas reduced soon after diagnosis, and did not catch up
during infancyor early childhoodwith routine clinical care.Wehave
been performing IPFTs using the raised volume rapid thor-
acoabdominal compression (RVRTC) technique8 and whole-body
plethysmography9 (IPL, Collins Medical, Louisville, CO) as a part of
routine clinical care in CF patients six months to three years of age.
Here we report two cases where IPFTs detected lung disease in
young patients with CF that was not suspected by clinical assess-
ment. The results were used to guide our clinical decision making
and to document response to therapy. The use of IPFTs in guiding
therapy, to our knowledge, has not been reported in infants with CF.2. Case 1
A.E. was a term infant who presented with Pseudomonas aeru-
ginosa (P. aeruginosa) urosepsis and lung infection (positive throat
culture) at 5 months of age. She was diagnosed with CF thereafter
(sweat chloride 104 mEq/L and CFTR genotype DF508 and
1898þ 1 G>A). Following three weeks of intravenous antibiotic
therapy for her acute infection (Ceftazidime and gentamicin), her
clinical condition improved. She was started on bronchodilators,
chest physiotherapy, pancreatic enzyme supplementation and fat
soluble vitamins. Follow-up throat culture was negative for
P. aeruginosa.
At 9 months of age she developed cough and P. aeruginosa was
grown from a routine throat culture. Chest X-ray scores was 22
using the Brasﬁeld scoring system.10 This was treated with oral
sulfamethoxazole and trimethoprim (SMZ/TMP) for 21 days as an
outpatient with improvement in her symptoms. In addition, daily
nebulized dornase alpha and budesonide were started at that time.
Symptoms resolved completely.
Fig. 1. Flow volume curves from Case 1 (a) and Case 2 (b). Single best curve at baseline (black line) and post intravenous antibiotics (gray line) are shown.
A.G. Filbrun et al. / Respiratory Medicine CME 4 (2011) 17–1918At 16 months of age she again developed cough and throat
cultures showed P. aeruginosa. Tobramycin solution for inhalation
(TSI) was initiated at a dose of 300 mg twice a day; 28 days on
followed by 28 days off in addition to a 21 day course of SMZ/TMP.
She improved symptomatically. Chest X-ray Brasﬁeld score was
23.10 Throat cultures subsequent to this grew only Staphylococcus
aureus (S. aureus) and Stenotrophomonas maltophilia (S. malto-
philia). Her weight remained stable in the 25th percentile for age
and length 20th percentile.
Baseline IPFTs were performed using the RVRTC technique and
whole-body plethysmography when equipment became available
at our institution, at 17 months of age (Fig. 1a). At the time of the
study her examwas within normal limits and her parents reported
occasional/intermittent coughwithout respiratory difﬁculty, fevers,
or audible wheezing. The patient had been at her baseline for at
least 3 weeks without acute URI symptoms. The study demon-
strated severe airﬂow obstruction particularly in the low ﬂow
ranges and evidence of gas trapping with an elevated residual
volume (RV) and RV to total lung capacity (TLC) ratio (Table 1).
These ﬁndings prompted the decision to hospitalize the patient
for treatment with parenteral antibiotics. Her chest X-ray Brasﬁeld
score on admission was 21. She was treated with a 21 day course of
intravenous ceftazidime and gentamicin. Her throat culture grew S.
maltophilia and oral ﬂora. Per parental report, she had resolution of
hermild symptomsanda signiﬁcant increase in energyandappetite.
Repeat pulmonary function testing at 19 months of age showed
signiﬁcant improvement in airﬂow (Table 1, Fig. 1a). Gas trappingTable 1
Pulmonary function results at baseline, following intravenous antibiotic therapy,
and at 6 and 12 month follow-up visits, given in percent of predicted.a,b











FVC, ml 67% 80% 98% 94% 108% 104% 92%
FEV0.5, ml 53% 88% 98% 75% 114% 107% 100%
FEV0.5/FVC 79% 110% 99% 81% 105% 102% 108%
FEF50, ml/s 32% 101% 128% 47% 101% 119% 133%
FEF75, ml/s 12% 94% 61% 28% 121% 84% 95%
FEF25–75,
ml/s
30% 98% 98% 39% 120% 109% 120%
TLC, ml 82% 97% 98% 86% 97% 81% 82%
FRCpleth, ml 133% 132% 128% 89% 83% 61% 91%
RV, ml 145% 167% 128% 89% 77% 49% 81%
RV/TLC 172% 167% 128% 99% 77% 58% 97%
a Predicted for spirometry5.
b Predicted for fractional lung volumes7.did not change. Notably in the 2 months after her treatment course
she demonstrated robust weight gain of 0.75 kg which increased
her to the 37th percentile from the 25th percentile for age.
Follow-up IPFTs 6 months later demonstrated stable lung
function, with a mild decline in FEF75, but improvement in air
trapping (Table 1). She continued to do well with no cough. Her
weight was at the 20th percentile for age.
3. Case 2
A.N. was a term female infant who presented with meconium
ileus that was successfully treated with two barium enemas. There
was a family history of CF and genetic testing revealed two disease
causing mutations in the CFTR gene (R347P and G542X).
At 2 weeks of age, she was started on bronchodilators, chest
physiotherapy, pancreatic enzyme supplements and fat soluble
vitamins. Early screening throat cultures grew Klebsiella pneumo-
niae (K. pneumoniae) which was treated with 14 days of oral
amoxicillin and clavulanate. Because of intermittent mild cough
symptoms, inhaled dornase alpha was started at 2 months of age.
Inhaled corticosteroids were started at 4 months of age for
persistent wheezing. Throat cultures at 5 months of age grew
Acinetobacter species and S. maltophilia. Oral SMZ/TMP was given
for 21 days at this time due to coughing. Chest X-ray Brasﬁeld score
was 23. Her symptoms improved after the antibiotic course. Her
weight remained at the 80th percentile for age.
IPFTs were performed at 6 months of age (Fig. 1b). At the time of
the study, the parents reported a history of occasional daytime
nonproductive cough and her exam was within normal limits. The
study revealedmoderate to severe airﬂow obstruction, especially in
the low ﬂow ranges. Lung volumes were within the normal range
(Table 1).
Based on the IPFT results, the patient was treatedwith 14 days of
intravenous ceftazidime and gentamicin. On admission her chest
X-ray Brasﬁeld score was 22. Throat culture on admission grew
moderate S. aureus, few K. pneumoniae, and rare quantities of
S. maltophilia and Acinetobacter species. Parents noted resolution of
her mild respiratory symptoms by the third day of therapy and at
discharge the patient was asymptomatic.
Follow-up IPFTs were performed 1 month after completion of
therapy. She was asymptomatic and had been at her baseline for at
least 3 weeks. This study showed normalization of the FEV0.5, FEF75
and FEF25–75 (Table 1). Lung volumes remained in the normal range.
Her weight increased by 0.9 kg in the interval between tests.
IPFTs were repeated at 6 and 12 months following treatment
and remained stable, without signiﬁcant decline (Table 1). A.N.
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twice for sinusitis with oral antibiotics in the 12 month follow-up
period. Her symptoms resolved completely following treatment.
She did not require parenteral antibiotics or hospitalization. She
continued to grow well with weights consistently above the 50th
percentile.
4. Discussion
The dilemma for the clinician caring for infants with CF is how to
best objectively assess and treat early lung disease tomaintain good
lung health for as long as possible. Unfortunately, subjective
assessments of symptoms may correlate poorly with the degree of
lung pathology. In older children with CF, correlation of cough with
pulmonary function is imprecise.11 In infants, clinical changes such
as new inﬁltrates on chest X-ray, failure to thrive, or new crackles
on exam make decisions to pursue more aggressive therapies easy
to justify. However, in the absence of these ﬁndings it can be
difﬁcult to judge when it is most appropriate to intervene with
additional or more intensive therapies. Techniques like HRCT and
bronchoscopy may be helpful in obtaining additional information
about airway pathology but are not used on a routine basi.12–14
Here we present two cases where IPFTs revealed an unexpected
degree of airway pathology that altered our clinical decision
making. The subjective reports of respiratory symptoms by the
parents were mild in both cases and alone would not have
prompted hospitalization and intravenous antibiotic therapy. In
these two cases, we feel that without IPFTs we would have delayed
aggressive treatment due to a reliance solely on assessment of signs
and symptoms.
Abnormal pulmonary function in CF infants and progressive
decline in the ﬁrst several years of life has been documented
previously.5 Our center’s experience to date concurs with this
ﬁnding. In the 17 CF infants we have tested to date, we found
Z-scores for FVC, FEV0.5, FEF75 and FEF25–75 to be 0.731.2,
0.531.0, 0.61 .98 and 0.02 0.80, respectively which are
comparable to other studies.5 Overall our average FVC was 9116%
of predicted (mean sd), FEV0.5 9414%, FEF75 87 25% and
FEF25–75 is 10117%. Compared to the other CF patients in our
population who have been tested, these two cases showed an
abnormal degree of airﬂow obstruction that fell far outside the
normal range for our cohort (Z-score<4 for FEF75 in each case).
Ranganathan and colleagues5 reported that despite treatment in
specialized CF centers, pulmonary function in infants with CF did
not improve, or show ‘‘catch-up’’ growth in infancy and early
childhood. Our cases demonstrate that this may not be universally
applicable as we were able to document a dramatic improvement
in pulmonary functionwith parenteral antibiotics andmaintenance
of normal lung function for 6–12 months after therapy. We would
suggest that a potential explanation for this difference is that the
previous study did not use IPFT results to guide therapy as is
routinely implemented in older children. Our cases highlight the
fact that with standard clinical care alone, even in a CF Center,
dramatic reductions in pulmonary function can be difﬁcult to
detect. However, when such abnormalities in lung function are
identiﬁed in infants and treated aggressively, pulmonary function
can be normalized.We were able to establish that our therapeutic interventions
were sufﬁcient by both subjective improvement in the patients’
respiratory status per parental report andbyobjective improvement
in lung function as assessed by IPFTs. These ﬁndings concur with
previous studies that have shown pulmonary function in CF infants
improves with inpatient antibiotic treatment.15 However, the deci-
sion to treat patients in this study was based on clinical criteria that
did not include PFT data. We feel that initiating intravenous antibi-
otics in our patients due to moderate to severe obstruction on IPFTs
helped us intervene earlier, and may have prevented morbidity and
a more rapid deterioration in pulmonary status.
These cases demonstrate the potential utility of IPFTs in guiding
the management of infants with CF. In our experience, we have had
no complications from sedation for IPFTs to date and we ﬁnd the
procedure safe and well tolerated. We believe that IPFTs are
a valuable tool in assessing and managing CF patients especially
those with mild lung disease. We feel that IPFTs could be instru-
mental in allowing early intervention and treatment of airway
disease in CF patients. This can have long term beneﬁts in
improving overall health and quality of life in these patients.
A larger prospective study would be of interest to further evaluate
whether using IPFTs to guide therapy in infants with CF would lead
to long term improvement in pulmonary function.References
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